<img alt="" src="https://secure.lote1otto.com/219869.png" style="display:none;">
Skip to content

Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Quantitative Strategies for Rare Disease Clinical Trials

Rare disease studies have specific challenges, such as small populations, limited prior knowledge on a disease, and difficulty in defining appropriate endpoints. Effective clinical development strategy for rare diseases requires agility to adapt to accumulating learning.

Here, we provide a brief overview on the construction of endpoints, adaptive and seamless clinical trial designs, Bayesian approaches, and the use of natural history studies in the development of rare disease studies.

Read full article
Perspectives on Enquiry and Evidence
October 7, 2014

You Own This!

Guest blogger Laurie Halloran is the President and CEO of Halloran Consulting Group, a management consulting firm for...
Read article
contact iconSubscribe back to top